Skip to main content
. 2008 Jan 15;35(1):24–30. doi: 10.1159/000112044

Fig. 2.

Fig. 2

a LIC by SQUID biosusceptometry under continuous erythrocytapheresis treatment in 4 patients with sickle cell disease. Median LIC for SCD under blood transfusion treatment according to [15]. b Ferritin-to-LIC ratio under continuous erythrocytapheresis treatment in 4 patients with sickle cell disease. Expected interquartile range for SCD under blood transfusion treatment according to [15].